Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options

被引:309
作者
Chang, Ya-Ting [1 ,2 ]
Lin, Chun-Yu [2 ,3 ]
Chen, Yen-Hsu [2 ,3 ,4 ]
Hsueh, Po-Ren [5 ,6 ]
机构
[1] Kaohsiung Municipal HsiaoKang Hosp, Div Infect Dis, Dept Internal Med, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Div Infect Dis, Dept Internal Med, Kaohsiung Med Univ Hosp, Kaohsiung 807, Taiwan
[3] Kaohsiung Med Univ, Sch Med, Grad Inst Med, Sepsis Res Ctr,Coll Med, Kaohsiung 807, Taiwan
[4] Natl Chiao Tung Univ, Coll Biol Sci & Technol, Dept Biol Sci & Technol, Hsinchu, Taiwan
[5] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Lab Med, Taipei 100, Taiwan
[6] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Taipei 100, Taiwan
关键词
Stenotrophomonas maltophilia; prevalence; susceptibility; surveillance; treatment; SENTRY ANTIMICROBIAL SURVEILLANCE; GRAM-NEGATIVE BACILLI; IN-VITRO ACTIVITY; BLOOD-STREAM INFECTION; INTENSIVE-CARE UNITS; URINARY-TRACT-INFECTIONS; MULTIDRUG EFFLUX PUMP; PROGRAM NORTH-AMERICA; VENTILATOR-ASSOCIATED PNEUMONIA; BETA-LACTAMASE PRODUCTION;
D O I
10.3389/fmicb.2015.00893
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Stenotrophomonas maltophilia is a Gram-negative, biofilm-forming bacterium. Although generally regarded as an organism of low virulence, S. maltophilia is an emerging multi-drug resistant opportunistic pathogen in hospital and community settings, especially among immunocompromised hosts. Risk factors associated with S. maltophilia infection include underlying malignancy, cystic fibrosis, corticosteroid or immunosuppressant therapy, the presence of an indwelling central venous catheter and exposure to broad spectrum antibiotics. In this review, we provide a synthesis of information on current global trends in S. maltophilia pathogenicity as well as updated information on the molecular mechanisms contributing to its resistance to an array of antimicrobial agents. The prevalence of S. maltophilia infection in the general population increased from 0.8-1.4% during 1997-2003 to 1.3-1.68% during 2007-2012. The most important molecular mechanisms contributing to its resistance to antibiotics include beta-lactamase production, the expression of Qnr genes, and the presence of class 1 integrons and efflux pumps. Trimethoprim/sulfamethoxazole (TMP/SMX) is the antimicrobial drug of choice. Although a few studies have reported increased resistance to TMP/SMX, the majority of studies worldwide show that S. maltophilia continues to be highly susceptible. Drugs with historically good susceptibility results include ceftazidime, ticarcillin-clavulanate, and fluoroquinolones; however, a number of studies show an alarming trend in resistance to those agents. Tetracyclines such as tigecycline, minocycline, and doxycycline are also effective agents and consistently display good activity against S. maltophilia in various geographic regions and across different time periods. Combination therapies, novel agents, and aerosolized forms of antimicrobial drugs are currently being tested for their ability to treat infections caused by this multi-drug resistant organism.
引用
收藏
页数:20
相关论文
共 187 条
[1]   Infections caused by Stenotrophomonas maltophilia in recipients of hematopoietic stem cell transplantation [J].
Al-Anazi, Khalid Ahmed ;
Al-Jasser, Asma M. .
FRONTIERS IN ONCOLOGY, 2014, 4
[2]   Molecular cloning and characterization of SmrA, a novel ABC multidrug efflux pump from Stenotrophomonas maltophilia [J].
Al-Hamad, Arif ;
Upton, Mathew ;
Burnie, James .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (04) :731-734
[3]   Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia [J].
Alonso, A ;
Martínez, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3079-3086
[4]   Stenotrophomonas maltophilia Infection Among Young Children in a Cardiac Intensive Care Unit: A Single Institution Experience [J].
Arthur, Ciji ;
Tang, Xinyu ;
Romero, Jose R. ;
Gossett, Jeffrey G. ;
Harik, Nada ;
Prodhan, Parthak .
PEDIATRIC CARDIOLOGY, 2015, 36 (03) :509-515
[5]   Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates [J].
Barbolla, R ;
Catalano, M ;
Orman, BE ;
Famiglietti, A ;
Vay, C ;
Smayevsky, J ;
Centrón, D ;
Piñeiro, SA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :666-669
[6]   Delafloxacin for the treatment of respiratory and skin infections [J].
Bassetti, Matteo ;
Della Siega, Paola ;
Pecori, Davide ;
Scarparo, Claudio ;
Righi, Elda .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (03) :433-442
[7]   SYNERGY WITH DOUBLE AND TRIPLE ANTIBIOTIC COMBINATIONS COMPARED [J].
BERENBAUM, MC ;
YU, VL ;
FELEGIE, TP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 (06) :555-563
[8]   Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia [J].
Betts, J. W. ;
Phee, L. M. ;
Woodford, N. ;
Wareham, D. W. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2014, 33 (09) :1565-1572
[9]   The Efflux Pump SmeDEF Contributes to Trimethoprim-Sulfamethoxazole Resistance in Stenotrophomonas maltophilia [J].
Blanca Sanchez, Maria ;
Luis Martinez, Jose .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) :4347-4348
[10]   Antimicrobial Susceptibility of Inpatient Urinary Tract Isolates of Gram-Negative Bacilli in the United States: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009-2011 [J].
Bouchillon, Sam K. ;
Badal, Robert E. ;
Hoban, Daryl J. ;
Hawser, Stephen P. .
CLINICAL THERAPEUTICS, 2013, 35 (06) :872-877